Scantox Group Expands Its Service Offerings
Today is a pivotal day for Scantox Group as it successfully acquires Gentronix Ltd, a well-respected name in genetic toxicology. This strategic move, made in collaboration with their majority owner, Impilo, significantly enhances Scantox's capabilities as a Contract Research Organization (CRO) that supports essential pre-IND studies.
Broadening the Service Platform
Gentronix, recognized for its dedication to high-quality genetic toxicology services, is now integrated into Scantox Group. With a solid track record that spans 25 years, Gentronix has served the pharma, biotech, and agrichem industries. It has built a strong reputation for helping clients identify genotoxic compounds early and supporting crucial development stages.
Innovative Solutions Available
Among the key services offered by Gentronix is the OECD 488 Big Blue® Transgenic Rodent Mutation assay, making it one of just three global providers of this vital service. Furthermore, Gentronix excels in ocular and skin toxicology endpoints, enhancing its service portfolio. This integration into Scantox Group is set to broaden the range of services available to meet client needs effectively.
Insights from Leadership
Jeanet Løgsted, CEO of Scantox Group, shared her excitement about the acquisition, stating, "Partnering with Gentronix brings genetic toxicology into our service offerings, which is often requested by our clients. Their exceptional service quality and culture align seamlessly with our vision. We aim to continuously expand our offerings and elevate scientific excellence within the Group."
Future Collaborations and Opportunities
Similarly, Matt Tate, CEO of Gentronix, expressed optimism about the new opportunities this acquisition presents. Tate noted, "Joining Scantox Group enables us to broaden our service portfolio, and we look forward to working closely with our new colleagues. There are many commercial synergies to explore together, enhancing our ability to provide world-class research services to our clients."
Wider Implications for Scantox Group
Following this acquisition, Gentronix will maintain its operations under its established name while expanding its regulatory toxicology services. This integration will help Scantox Group exceed 400 employees across various European locations, solidifying its position as a leading provider of lead optimization, regulatory toxicology, and analytical services.
Strategic Growth Prospects
Nicholas Hooge, Partner at Impilo, emphasized the growth potential associated with this acquisition, stating, "The addition of Gentronix to the Scantox Group represents significant growth opportunities. The year 2024 is set to be transformative for Scantox, marking key milestones toward achieving our strategic goals."
Frequently Asked Questions
What is the significance of Scantox acquiring Gentronix?
This acquisition enhances Scantox's capabilities in genetic toxicology and significantly expands its service offerings.
How long has Gentronix been in operation?
Gentronix has been providing its services for 25 years, gaining extensive experience in the field of genetic toxicology.
What are Gentronix's main service offerings?
Gentronix specializes in genetic toxicology solutions, including regulatory assessments and genotoxicity assays.
How many employees will Scantox Group have after this acquisition?
After the acquisition, Scantox Group will employ over 400 staff across its European locations.
Who leads Scantox Group and Gentronix?
Jeanet Løgsted is the CEO of Scantox Group, while Matt Tate serves as the CEO of Gentronix.
